You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Pretreatment with the Free Radical Scavenger Edaravone Prevents Cerebral Hyperperfusion after Carotid Endarterectomy

Ogasawara, Kuniaki M.D.; Inoue, Takashi M.D.; Kobayashi, Masakazu M.D.; Endo, Hidehiko M.D.; Fukuda, Takeshi M.D.; Ogawa, Akira M.D.

Neurosurgery:
doi: 10.1227/01.NEU.0000140838.27450.63
Clinical Studies
Abstract

OBJECTIVE: Cerebral hyperperfusion syndrome after carotid endarterectomy (CEA) is a rare but potentially devastating complication. The purpose of the present study, which was not a randomized controlled trial but a case cohort study with historical control, was to determine whether pretreatment with a novel free radical scavenger, edaravone, could prevent occurrence of cerebral hyperperfusion after CEA.

METHODS: Fifty patients with ipsilateral internal carotid artery stenosis (≥70%) underwent CEA with administration of edaravone before internal carotid artery clamping. Preoperative cerebral blood flow and cerebrovascular reactivity (CVR) to acetazolamide were assessed with single-photon emission computed tomography (SPECT). Cerebral blood flow also was measured immediately after CEA and on the 3rd postoperative day.

RESULTS: Cerebral hyperperfusion (cerebral blood flow increase ≥100% compared with preoperative values) was revealed by SPECT performed immediately after CEA in only one patient (2%), who also exhibited reduced preoperative CVR. The incidence of post-CEA hyperperfusion as revealed by SPECT in the control group (51 CEA patients without administration of edaravone) was significantly higher (16%) (P = 0.0310, control versus treatment group). In addition, in a subgroup of patients with reduced preoperative CVR, the incidence of post-CEA hyperperfusion as revealed by SPECT in the edaravone group (7%) was significantly lower than that in the control group (67%) (P = 0.0029). Logistic regression analysis demonstrated that reduced preoperative CVR and absence of pretreatment with edaravone were significant independent predictors of post-CEA hyperperfusion as revealed by SPECT.

CONCLUSION: Pretreatment with edaravone can prevent occurrence of cerebral hyperperfusion after CEA.

Author Information

Department of Neurosurgery, Iwate Medical University, Morioka, Japan (Ogasawara, Inoue, Kobayashi, Endo, Fukuda, Ogawa)

Reprint requests: Kuniaki Ogasawara, M.D., Department of Neurosurgery, Iwate Medical University, 19-1 Uchimaru, Morioka, Japan 020-8505. Email: kuogasa@iwate-med.ac.jp

Received, January 14, 2004.

Accepted, June 7, 2004.

Copyright © by the Congress of Neurological Surgeons